T. Schwarz

发表

A Therapeutic Non-self-reactive SARS-CoV-2 Antibody Protects from Lung Pathology in a COVID-19 Hamster Model

M. Endres, I. Wilson, A. Gruber, 2020, Cell.

A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model

M. Endres, I. Wilson, A. Gruber, 2020, bioRxiv.

A Sars-Cov-2 Neutralizing Antibody Protects from Lung Pathology in a Covid-19 Hamster Model

I. Wilson, A. Gruber, M. Höltje, 2020 .

Disease Severity, Fever, Age, and Sex Correlate With SARS-CoV-2 Neutralizing Antibody Responses

H. Volk, C. Scheibenbogen, M. Müller, 2021, Frontiers in Immunology.

Comparison of potency assays to assess SARS-CoV-2 neutralizing antibody capacity in COVID-19 convalescent plasma

B. Schnierle, V. Corman, T. Tonn, 2020, Journal of Virological Methods.

HCoV- and SARS-CoV-2 Cross-Reactive T Cells in CVID Patients

H. Volk, C. Scheibenbogen, V. Corman, 2020, Frontiers in Immunology.

Humoral immune responses remain quantitatively impaired but improve qualitatively in anti-CD20-treated patients with multiple sclerosis after three or four COVID-19 vaccinations

V. Corman, C. Drosten, K. Ruprecht, 2022, medRxiv.

Phenotype and function of HBV-specific T cells is determined by the targeted epitope in addition to the stage of infection

G. Lauer, R. Chung, A. Boonstra, 2018, Gut.

Pausing methotrexate improves immunogenicity of COVID-19 vaccination in elderly patients with rheumatic diseases

G. Burmester, V. Corman, C. Drosten, 2022, Annals of the Rheumatic Diseases.

Preserved T cell responses to SARS-CoV-2 in anti-CD20 treated multiple sclerosis

V. Corman, C. Drosten, K. Ruprecht, 2022, Multiple sclerosis.

A cohort of 222 anti-CD20 treated patients with multiple sclerosis followed through the COVID-19 pandemic: Attenuated humoral but robust cellular immune responses after vaccination and infection

V. Corman, C. Drosten, K. Ruprecht, 2021, medRxiv.

Long-term immunogenicity of BNT162b2 vaccination in older people and younger health-care workers

N. Suttorp, V. Corman, C. Drosten, 2021, The Lancet Respiratory Medicine.

Impact of dexamethasone on SARS-CoV-2 concentration kinetics and antibody response in hospitalized COVID-19 patients: results from a prospective observational study

C. von Kalle, F. Tacke, Sebastian Albus, 2021, Clinical Microbiology and Infection.

Cutting Edge: Serum but Not Mucosal Antibody Responses Are Associated with Pre-Existing SARS-CoV-2 Spike Cross-Reactive CD4+ T Cells following BNT162b2 Vaccination in the Elderly

I. Demuth, A. Thiel, L. Henze, 2022, The Journal of Immunology.

NK cells improve control of friend virus infection in mice persistently infected with murine cytomegalovirus

U. Dittmer, K. Gibbert, Anke Kraft, 2013, Retrovirology.

Immune escape pathways from the HBV core18-27 CD8 T cell response are driven by individual HLA class I alleles

T. Luedde, D. Hoffmann, H. Bock, 2022, Frontiers in Immunology.

Independent side-by-side validation and comparison of four serological platforms for SARS-CoV-2 antibody testing

E. Seifried, V. Corman, C. Drosten, 2020, The Journal of infectious diseases.

SARS-CoV-2 Proteome-Wide Analysis Revealed Significant Epitope Signatures in COVID-19 Patients

M. Müller, V. Corman, C. Drosten, 2021, Frontiers in Immunology.

Low Seroprevalence of SARS-CoV-2 Antibodies during Systematic Antibody Screening and Serum Responses in Patients after COVID-19 in a German Transplant Center

K. Budde, M. Naik, V. Corman, 2020, Journal of clinical medicine.

Safety, reactogenicity, and immunogenicity of homologous and heterologous prime-boost immunisation with ChAdOx1 nCoV-19 and BNT162b2: a prospective cohort study

C. von Kalle, N. Suttorp, D. Treue, 2021, The Lancet Respiratory Medicine.

Clinical Outcome and Viral Genome Variability of Hepatitis B Virus–Induced Acute Liver Failure

G. Gerken, A. Canbay, S. Ciesek, 2019, Hepatology.

Delayed Antibody and T-Cell Response to BNT162b2 Vaccination in the Elderly, Germany

C. von Kalle, N. Suttorp, V. Corman, 2021, Emerging infectious diseases.

Donors for SARS-CoV-2 Convalescent Plasma for a Controlled Clinical Trial: Donor Characteristics, Content and Time Course of SARS-CoV-2 Neutralizing Antibodies

E. Seifried, J. Pilch, R. Blasczyk, 2021, Transfusion Medicine and Hemotherapy.

Reactive T Cells in Convalescent COVID-19 Patients With Negative SARS-CoV-2 Antibody Serology

H. Volk, C. Scheibenbogen, V. Corman, 2021, Frontiers in Immunology.

Outbreak of SARS-CoV-2 B.1.1.7 Lineage after Vaccination in Long-Term Care Facility, Germany, February–March 2021

N. Suttorp, V. Corman, C. Drosten, 2021, Emerging infectious diseases.

Cross-reactive CD4+ T cells enhance SARS-CoV-2 immune responses upon infection and vaccination

K. Schnatbaum, U. Reimer, H. Wenschuh, 2021, Science.

SARS-CoV-2 Beta variant infection elicits potent lineage-specific and cross-reactive antibodies

I. Wilson, M. Hoelscher, D. Schmitz, 2021, bioRxiv.

Immunogenicity of COVID-19 Tozinameran Vaccination in Patients on Chronic Dialysis

A. Sattler, V. Corman, J. Lippert, 2021, Frontiers in Immunology.

SARS-CoV-2 T Cell Response in Severe and Fatal COVID-19 in Primary Antibody Deficiency Patients Without Specific Humoral Immunity

C. Meisel, S. Gläser, H. Volk, 2022, Frontiers in Immunology.

Impaired B Cell Recall Memory and Reduced Antibody Avidity but Robust T Cell Response in CVID Patients After COVID-19 Vaccination

C. Scheibenbogen, V. Corman, C. Drosten, 2023, Journal of Clinical Immunology.

Type of vaccine and immunosuppressive therapy but not diagnosis critically influence antibody response after COVID-19 vaccination in patients with rheumatic disease

G. Burmester, V. Corman, J. Klotsche, 2022, RMD Open.

Serum but not mucosal antibody responses are predicted by pre-existing SARS-CoV-2 spike cross-reactive CD4+ T cells following BNT162b2 vaccination in the elderly

I. Demuth, L. Henze, V. Corman, 2021, medRxiv.

Characterization of the SARS-CoV-2 Neutralization Potential of COVID-19–Convalescent Donors

E. Seifried, J. Münch, V. Corman, 2021, The Journal of Immunology.

Pausing methotrexate improves immunogenicity of COVID-19 vaccination in patients with rheumatic diseases

A. ten Hagen, C. Drosten, J. Klotsche, 2021, medRxiv.

Preclinical safety and efficacy of a therapeutic antibody that targets SARS-CoV-2 at the sotrovimab face but is escaped by Omicron

K. Eschke, V. Corman, H. Prüss, 2023, iScience.

Reactogenicity of homologous and heterologous prime-boost immunization with BNT162b2 and ChAdOx1-nCoV19: a prospective cohort study

N. Suttorp, D. Treue, V. Corman, 2021, medRxiv.

A bead-based multiplex assay covering all coronaviruses pathogenic for humans for sensitive and specific surveillance of SARS-CoV-2 humoral immunity

Martin Skiba, M. Grossegesse, Silke Stahlberg, 2023, Scientific reports.